Balstilimab + Botensilimab
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Colorectal Cancer
Conditions
Colorectal Cancer
Trial Timeline
Mar 31, 2026 → Jun 30, 2029
NCT ID
NCT07152821About Balstilimab + Botensilimab
Balstilimab + Botensilimab is a phase 3 stage product being developed by Agenus for Colorectal Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07152821. Target conditions include Colorectal Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07152821 | Phase 3 | Recruiting |
| NCT06843434 | Phase 2 | Recruiting |
Competing Products
20 competing products in Colorectal Cancer